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ABSTRACT
Bone marrow necrosis (BMN) in acute leukemia
is a rare histopathological entity at the time of
initial diagnosis. However, it represents an
important diagnostic and prognostic challenge.
Two cases of BMN are reported: a 44-year-old
patient with B cell precursor (BCP) acute lym-
phoblastic leukemia (ALL) and a 27-year-old
man with FAB-M5 acute myeloid leukemia
(AML) who both presented with bone marrow
failure and extensive necrosis. From these clin-
ical cases, we conducted a brief review of the
literature.
Keywords: Acute leukemia; Bone marrow
necrosis; Chemotherapy; Prognosis
INTRODUCTION
Bone marrow necrosis (BMN) is defined as a
necrosis of myeloid tissue and medullary stroma
in large areas of hematopoietic bone marrow,
without involvement of the cortical bone [6]. It
was first described by Wade and Stevenson in
1942 in a patient who had sickle cell disease [7].
It is an uncommon, but not rare cytological and
histological entity in both AML and ALL. The
clinical symptoms could be very severe with
fatigue, bone pains, fever and biological alter-
ations as anemia, thrombocytopenia, leucope-
nia or leukocytosis, coagulopathy, high LDH
level, and/or hypercalcemia [6]. The diagnosis is
made by bone marrow aspirates or biopsy, with
sometimes the presence of Charcot-Leyden
crystals [27]. The treatment is based on the
associated pathology. The prognosis is generally
poor, depending on age, patient clinical history
and severity of the initial pathology. The inci-
dence of BMN, seen across a wide range of
malignant and nonmalignant hematological
disorders, ranges from 0.5% to 33% [8]. The
differences observed in the literature in terms of
BMN rates can be explained in part by the use of
different grading scales. Paydas et al. described
23 cases (20 adults and three children) of BMN
among 1083 bone marrow biopsies that is a
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prevalence of 2.2% [9]. Badar et al. showed in a
more recent report, an incidence of 2.4% in
AML and 3.2% in ALL [10]. We report here two
cases of bone marrow necrosis (BMN): a 44-
year-old patient with B-cell precursor (BCP)
acute lymphoblastic leukemia (ALL) and a
27-year-old man with FAB-M5 acute myeloid
leukemia (AML) who both presented with bone
marrow failure and extensive necrosis.
Informed consent was obtained from all
patients for being included in the study.
CASE REPORT #1
A 44-year-old man was admitted in April 2014
for lumbar pains related to a paraspinal mass.
The patient had no prior medical history. At
admission, his complete blood count showed:
hemoglobin 129 g/L, platelet count 66 9 109/L,
and white blood cell count 4.7 9 109/L with 8%
of blast cells.
Bone marrow aspirate revealed a hypocellu-
lar marrow with extensive necrosis and pyc-
notic features in most of the cells (Fig. 1). Bone
marrow biopsy confirmed an extensive necrosis
([60%). Peripheral blood flow cytometry anal-
ysis revealed a BCP-common ALL profile:
CD45dim/SSClo, CD10?hi, CD20?, CD34-, and
CD38?hi, CD123-, CD44?hi, CD49f?/- with
negativity for myeloid or T lymphoid markers.
There was no central nervous system involve-
ment. Cytogenetic analysis did not revealed any
abnormality (46, XY on 20 analyzed mitosis).
FISH analysis and molecular analyses did not
show MLL amplification, BCR-ABL fusion gene,
or IKAROS gene deletion. The patient was
bFig. 1 Morphology of leukemia at diagnosis (case report
#1: BCP-ALL). a Blood smear showing small to medium
size blast cell, with ﬁne and pearly chromatin, evocative of
lymphoid blast. b Bone marrow aspirate picture in optic
microscopy (May–Gru¨nwald–Giemsa) showing extensive
marrow necrosis. Cells cannot be identiﬁed. c Bone
marrow trephine biopsy showing a ﬁbrotic marrow with a
low cellularity but a massive blastic inﬁltration
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treated according to the GRAALL-2005 protocol
[1]. Corticosensivity and chemosensivity were
evaluated on day 8 of treatment. At the end of
induction chemotherapy (day 35), a morpho-
logic complete response (CR) was obtained with
undetectable minimal residual disease (MRD)
based both on flow cytometry and molecular
analysis.
The patient received consolidation treat-
ment, without any major complication, but he
relapsed at the end of consolidation therapy.
Salvage therapy with blinatumomab (a
bi-specific monoclonal antibody binding
simultaneously to CD3-positive cytotoxic T
cells and CD19-positive B cells) was started
yielding to a second CR achievement. Further,
the patient underwent allogeneic hematopoi-
etic stem cell transplant from a sibling donor,
after myeloablative conditioning regimen
combining high-dose cyclophosphamide with
total body irradiation. The patient relapsed
again four months later. The third line therapy
consisted in the combination of Hyper-CVAD
regimen with epratuzumab (an anti-CD22
monoclonal antibody). Disease progression did
not permit obtaining a new response and the
patient died 17 months after the initial diag-
nosis from hemorrhagic and infectious
complications.
CASE REPORT #2
A 27-year-old man without significant prior
medical history was admitted in December 2014
for intense lumbar pains with right sciatalgia,
lumbago and hypoesthesia. The spinal CT scan
confirmed L5-S1 discarthrosis. He also pre-
sented a numb chin syndrome. At admission,
his complete blood count showed: hemoglobin
107 g/L, platelet count 62 9 109/L, and white
blood cell count 2.2 9 109/L with 6% of blast
cells. Bone marrow aspirate revealed extensive
necrosis of hematopoietic tissue (Fig. 2). How-
ever, some areas showed intact cells with
monoblast morphology, irregular nucleus, fine
chromatin, nucleolus, and an intense baso-
philic cytoplasm. Bone marrow biopsy con-
firmed an extensive necrosis ([60%), with
reticulinic fibrosis (grade 1), necrotic cells with
blast morphology, some of which showing ery-
throphagocytosis features. Bone marrow flow
cytometry immunophenotyping showed the
Fig. 2 Morphology of leukemia at diagnosis (case report
#2: AML). a Blood smear showing an aspect of myeloid
blasts with monocytic differentiation. b Bone marrow
aspirate picture in optic microscopy (May–Gru¨nwald–
Giemsa) showing extensive marrow necrosis. Cells cannot
be recognized, showing indistinct outlines and pycnotic
nuclei. c Bone marrow trephine biopsy showing a
hypercellular marrow with extensive necrosis. Majority of
cells are necrotic but however suggestive of blastic cells
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following profile: CD45dim/SSClo, CD34-,
CD38?hi, CD123?hi, HLADR?hi, CD13?/-,
CD33?hi, CD15?hi, CD117-, CD36?, CD4?lo,
CD11b?hi and CD56?hi, and negativity for
lymphoid markers. A diagnosis of AML of M5
subtype according to FAB classification was
established. The cytogenetic analysis revealed a
clonal aberration with 47, XX, ?8[4]/46,
XY[16], classified as intermediate-risk according
to the ELN criteria [2]. In molecular biology,
there was no EVI1, WT1, FLT3-ITD, MLL nor
CEBPA mutations or rearrangements, but
oneNPM1 mutation.
The patient received timed sequential
induction chemotherapy with two sequences
combining daunorubicin with cytarabine
according to the ALFA-0702 protocol [3].
Because of central nervous system involvement,
treatment was completed by intrathecal
chemotherapy administration. A morphologic
evaluation at the end of induction therapy
showed CR, an hypoplastic bone marrow and
the presence of 2–3% of immature cells, con-
firmed by flow cytometry (MRD = 1%) and
persistence of NPM1 positivity. The patient
relapsed with extramedullary localizations
(leukemia cutis, central nervous system
involvement) after consolidation chemother-
apy. The patient received two further lines of
treatment which did not allow any response
[4, 5]. He finally died 10 months after the initial
diagnosis.
DISCUSSION
As previously described, BMN is usually
observed in the setting of hematological
malignancies (60%) or solid tumor (30%)
[6, 11]. In a series of 240 BMN, Janssens showed
that ALL represented the most common
underlying disorder (18%). BMN was also fre-
quently associated with AML (13%). In this
series, BMN was observed at the time of diag-
nosis in 26 of 37 patients (70.3%), and only
after induction chemotherapy in one of 37
patients (20.7%), and at the time of recurrence
in ten of 37 patients (27%) [6]. In a series of 640
patients, Badar et al. reported that among
patients with AML and BMN, 32% had the
FAB-M5 subtype, compared to only 10% with-
out BMN.
Clinical symptoms of BMN are non-specific.
The most common is bone pain, which is
observed in 80% of the cases, and may be dis-
seminated or localized in the lower back [10].
Fever is also often seen in BMN (70% of the
cases) [9]. Both symptoms can be related to the
importance of tissue necrosis [9, 12]. Laboratory
findings often include anemia, thrombocy-
topenia, elevated lactate deshydrogenase and
alkaline phosphatase levels [11, 13].
Few data are currently available in the liter-
ature about the prognostic impact of BMN in
acute leukemia at the time of diagnosis. Only
one large series, describing BMN in 25 AML
patients (2.4%) and 20 ALL patients (3.2%),
demonstrated a low CR rate and a poor overall
outcome [10]. The presence of BMN was asso-
ciated with a worse outcome among AML
patients with a median overall survival (OS) of
only 3.7 months. OS in our cases were
17 months and 10 months respectively. In
Badar’s study, AML patients had a significantly
lower CR rate (32%) than those without BMN
(59%) (p = 0.008). Early death was observed in
three (12%) and 37 (3.6%) of patients with and
without BMN, respectively (p = 0.07). In ALL
patients, CR rate was also significantly lower
(70% vs 90%, p = 0.01) and 3% vs 1% had early
death (p = 0.44) [10].
Prognostic factors in BMN cases mainly
depend on patient age and the nature of the
underlying disease. The presence of BMN was
not reported of poor prognosis in children [14].
Pui et al. examined bone marrow specimens
from 1419 children with acute leukemia. BMN
was found in seven (0.5%) of them. Six (four
with ALL and two with neuroblastoma)
remained in long-term remission [15]. However,
McFarlane reported only one persistent CR on
four patients with BMN [16].
Bone marrow trephine biopsy appeared to be
essential for the diagnosis of BMN and for
necrosis grading. When bone marrow aspirate is
successful, cytology examination shows pyc-
notic cells, scarcely recognizable in a back-
ground of amorphous extracellular eosinophilic
material. Histology is more specific and char-
acterized by a combination of gelatinous
Oncol Ther
Table 1 Review of the literature
References Number of cases Underlying disease Treatment Outcome
Niebrugge and Benjamin
[14]
2 cases ALL IC DFS: 6 months?
DFS: 4 years?
Pui et al. [15] 7 cases/1419 5 ALL
2 neuroblastoma
IC ND
Forrest et al. [18] 10 cases/581 AL
NHL
IC ND





ND Median OS: 1 to
4 months







ND OS: few days to few
months
Eusni et al. [19] 1 case ALL IC Early death








1 case AML IC ND
Lackner et al. [21] 1 case HL IC ND
Shaﬁq and Ali [22] 1 case Sickle cell anemia SC ND
Koshnaw and
Muhealdeen [23]
1 case ALL IC CR
Shapiro et al. [24] 1 case Secondary AML IC Early death
Choudary et al. [11] 1 case Myeloﬁbrosis SC Early death
Badar et al. [13] 45 cases/1691 20 AML
25 ALL





transformation (hypoplasia and background of
amorphous eosinophilic staining material) and
necrosis of the myeloid tissue [6]. There is also a
disappearance of fat space while cortical bone is
preserved. BMN can be evaluated according to
three levels, depending on the necrotic area.
Grade I (\20%) corresponds to mild necrosis if
restricted to a focal area, grade II (20–50%) to
moderate necrosis if intermediate involvement
is seen, and grade III ([50%) if an extensive
involvement of the bone marrow is observed.
Moderate (Grade II) and severe (Grade III) bone
marrow necrosis are often associated with life
threatening illnesses [8].
Physiopathology of BMN is not fully eluci-
dated. BMN usually results from microvascular
failure, and is often associated with a hypercel-
lular marrow, except in aplastic anemia where
cellularity is generally decreased [11]. When the
microvasculature has been restored, the necro-
tic material may be removed by phagocytosis,
followed by reconstitution of bone marrow tis-
sue, with development of proliferating capil-
laries and fibroblasts. Repopulation of the
marrow by a normal hematopoietic tissue is
usually the rule, as observed in reported cases of
sickle cell anemia [9, 17]. In our cases, bone
marrow regeneration was consistently observed
after induction therapy. The occurrence of BMN
can be explained by hypoxemia following fail-
ure of the microcirculation. Mentioned causes
are vascular inflammatory lesions mediated by
immune complex deposition, or toxins and
cytokines (including TNFa) released by tumoral
cells [6, 9, 11]. Unexplained physiopathology
and poor prognosis is the characteristics of this
presentation. In a 10-year retrospective analysis
[28] approximately 0.3% of non–site-directed
bone marrow cases showed significant necrosis,
most of them secondary to metastatic tumor or
hematolymphoid malignancy (together, 90% of
necrosis cases). In this study, patients with
malignancy-associated marrow necrosis had
generally a poorer outcome (approximately
55% of mortality on follow-up regardless of
tumor type), although this could be related to
the poor prognosis of their underlying malig-
nancies. However, some surviving patients with
malignancy-associated marrow necrosis can
achieve durable remissions (up to 8 years) with
return to normal blood counts. We propose that
each bone marrow aspirate displaying necrosis
features should be completed by bone marrow
biopsy morphological examination in order to
determine the pattern and stage of cellular
necrosis, the search for infectious etiologies, the
presence of hematolymphoid malignancy,
nonnecrotic tumor cells, Charcot Leyden crys-
tals or other specific morphologic features
(Table 1).
CONCLUSIONS
In our institution, only two cases of acute leu-
kemia associated with severe BMN were seen
Table 1 continued
References Number of cases Underlying disease Treatment Outcome
Daskalakis and Caballero
[25]
1 case AML SC Early death
Rashidi et al. [26] 1 case AML IC ? ASCT ND
Chambers et al. [12] 1 case Secondary AML SC Early death
Our study 2 cases 1 ALL
1 AML
IC OS: 17 months
OS: 10 months
AL acute leukemia, ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, ASCT allogeneic stem cell trans-
plantation, CML chronic myeloid leukemia, CR complete remission, DFS disease-free survival, HL Hodgkin lymphoma,
HU hydroxyurea, IC intensive chemotherapy, MDS myelodysplastic syndrome, ND not done, NHL non Hodgkin lym-
phoma, OS overall survival, SC supportive care
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over the last ten years, among more than 1000
newly diagnosed AML and 500 newly diagnosed
ALL. Despite intensive therapy, the outcome
was rapidly pejorative with relapse and death
occurring after few months. In accordance with
the literature, BMN may be considered as an
adverse prognosis factor. Early identification of
BMN in newly diagnosed acute leukemia may
be helpful for establishing prognostic stratifica-
tion and treatment-decision making, especially
in patients without any other unfavorable
prognostic markers. Given the extreme rarity of
this entity, only international collaborative
studies could better elucidate the clinical
impact of BMN, as an independent prognostic
factor in acute leukemia.
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